Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

UBS Downgrades Mylan Labs to 'Neutral'

UBS Financial downgraded Mylan Labs (MYL) to neutral from buy.

Analyst Steven Valiquette says he's downgrading on revised estimates for the company's generic Duragesic drug for pain. He had thought generic Duragesic would be a key catalyst for Mylan's stock, but an analysis of post-trial briefs leads him to believe that Mylan now has less than a 50/50 chance of winning a patent dispute with Johnson & Johnson.

Valiquette expects the patent ruling to occur in either December or January. He removed $50 million of generic Duragesic revenues from his fiscal 2004 (Mar.) estimate, and cut the $200 million fiscal 2005 generic Duragesic revenue estimate to $40 million.

He also lowered the $1.20 fiscal 2004 earnings per share estimate to $1.16, and trimmed the $1.45 fiscal 2005 estimate to $1.30. Finally, Valiquette cut the $31 target to $24.

blog comments powered by Disqus